Cargando…
Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
Hepatocellular carcinoma (HCC), with its ineffective therapeutic options and poor prognosis, represents a global threat. In the present study, we show that RAD52 motif 1 (RDM1), a key regulator of DNA double‐strand break repair and recombination, is downregulated in HCC tissues and suppresses tumor...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998392/ https://www.ncbi.nlm.nih.gov/pubmed/31670863 http://dx.doi.org/10.1002/1878-0261.12593 |
_version_ | 1783493842156126208 |
---|---|
author | Chen, Shi‐Lu Liu, Li‐Li Wang, Chun‐Hua Lu, Shi‐Xun Yang, Xia He, Yang‐Fan Zhang, Chris Zhiyi Yun, Jing‐Ping |
author_facet | Chen, Shi‐Lu Liu, Li‐Li Wang, Chun‐Hua Lu, Shi‐Xun Yang, Xia He, Yang‐Fan Zhang, Chris Zhiyi Yun, Jing‐Ping |
author_sort | Chen, Shi‐Lu |
collection | PubMed |
description | Hepatocellular carcinoma (HCC), with its ineffective therapeutic options and poor prognosis, represents a global threat. In the present study, we show that RAD52 motif 1 (RDM1), a key regulator of DNA double‐strand break repair and recombination, is downregulated in HCC tissues and suppresses tumor growth. In clinical HCC samples, low expression of RDM1 correlates with larger tumor size, poor tumor differentiation, and unfavorable survival. In vitro and in vivo data demonstrate that knockdown of RDM1 increases HCC cell proliferation, colony formation, and cell population at G2/M phase, whereas RDM1 overexpression results in the opposite phenotypes. Mechanistically, RDM1 binds to the tumor suppressor p53 and enhances its protein stability. In the presence of p53, RDM1 suppresses the phosphorylation of Raf and ERK. Overexpression of p53 or treatment with ERK inhibitor significantly abolishes cell proliferation induced by the depletion of RDM1. In addition, overexpression of methyltransferase‐like 3 markedly induces N6‐methyladenosine modification of RDM1 mRNA and represses its expression. Taken together, our study indicates that RDM1 functions as a tumor suppressor and may be a potential prognostic and therapeutic factor for HCC. |
format | Online Article Text |
id | pubmed-6998392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69983922020-02-05 Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways Chen, Shi‐Lu Liu, Li‐Li Wang, Chun‐Hua Lu, Shi‐Xun Yang, Xia He, Yang‐Fan Zhang, Chris Zhiyi Yun, Jing‐Ping Mol Oncol Research Articles Hepatocellular carcinoma (HCC), with its ineffective therapeutic options and poor prognosis, represents a global threat. In the present study, we show that RAD52 motif 1 (RDM1), a key regulator of DNA double‐strand break repair and recombination, is downregulated in HCC tissues and suppresses tumor growth. In clinical HCC samples, low expression of RDM1 correlates with larger tumor size, poor tumor differentiation, and unfavorable survival. In vitro and in vivo data demonstrate that knockdown of RDM1 increases HCC cell proliferation, colony formation, and cell population at G2/M phase, whereas RDM1 overexpression results in the opposite phenotypes. Mechanistically, RDM1 binds to the tumor suppressor p53 and enhances its protein stability. In the presence of p53, RDM1 suppresses the phosphorylation of Raf and ERK. Overexpression of p53 or treatment with ERK inhibitor significantly abolishes cell proliferation induced by the depletion of RDM1. In addition, overexpression of methyltransferase‐like 3 markedly induces N6‐methyladenosine modification of RDM1 mRNA and represses its expression. Taken together, our study indicates that RDM1 functions as a tumor suppressor and may be a potential prognostic and therapeutic factor for HCC. John Wiley and Sons Inc. 2019-12-19 2020-02 /pmc/articles/PMC6998392/ /pubmed/31670863 http://dx.doi.org/10.1002/1878-0261.12593 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Chen, Shi‐Lu Liu, Li‐Li Wang, Chun‐Hua Lu, Shi‐Xun Yang, Xia He, Yang‐Fan Zhang, Chris Zhiyi Yun, Jing‐Ping Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways |
title | Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways |
title_full | Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways |
title_fullStr | Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways |
title_full_unstemmed | Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways |
title_short | Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways |
title_sort | loss of rdm1 enhances hepatocellular carcinoma progression via p53 and ras/raf/erk pathways |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998392/ https://www.ncbi.nlm.nih.gov/pubmed/31670863 http://dx.doi.org/10.1002/1878-0261.12593 |
work_keys_str_mv | AT chenshilu lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways AT liulili lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways AT wangchunhua lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways AT lushixun lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways AT yangxia lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways AT heyangfan lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways AT zhangchriszhiyi lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways AT yunjingping lossofrdm1enhanceshepatocellularcarcinomaprogressionviap53andrasraferkpathways |